Keyword: Vertex Pharmaceuticals
The FDA lifted a clinical hold it placed on Vertex and CRISPR Therapeutics’ gene-edited stem cell therapy for sickle cell disease.
Inscripta aims to broaden access to CRISPR by offering new enzymes for free, and to boost R&D by outfitting scientists with a full suite of tools.
CRISPR Therapeutics and Vertex Pharmaceuticals will test their gene therapy in patients with beta thalassemia.
The partnership will leverage a platform that collates and analyzes genotype-phenotype studies to uncover insights into the underpinnings of disease.
Gilead's clinical director joins Nimbus to lead discovery; Immunocore’s CMO jumps to Tmunity; Kite taps Eisai vet to lead CAR-T sales.
Syntimmune has named Vertex’s Mario Saltarelli as chief medical officer, following several leadership changes at the company over the past 18 months.
The action prompted Galapagos to review the future of its relationship with AbbVie—and provided a boost to cystic fibrosis rival Vertex.
Vertex's newly expanded site covers 170,000 square feet, boosting Vertex’s ability to hunt for the next generation of blockbusters.
Shares in CRISPR fell 15% as investors digested the delay to the start of the gene-editing startup’s first U.S. clinical trial.
Vertex says its long-acting version of Kalydeco has been held up by an FDA data request—but analysts think it could be a bigger issue for its rivals.